However , because of recurrent ischemic events in high risk patients there was a basis for development of antiplatelet drugs to target other important signaling pathways .
Before the time of ADP inhibitors the only antiplatelet agent on the market to treat antithrombotic events was aspirin .
Because of recurrent ischemic events in high risk patients there was a basis for development of antiplatelet drugs to target other important signaling pathways .
Before the time of ADP inhibitors the only antiplatelet agent on the market to treat antithrombotic events was aspirin .